2 In our clinical experience, approximately 20% of patients with moderate-to-severe psoriasis are currently treated with anti-TNF agents including etanercept, infliximab and adalimumab.

adds specificity by showing a moderately increased risk of herpes zoster in patients receiving anti-TNF antibody ... treated with the TNF receptor fusion protein etanercept, although this increase ...

2010 Future Medicine Ltd. Cite this: Anti-TNF-α Agents in the Treatment of Immune-mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls - Medscape - Nov 01, 2010.

Furthermore, clinical and experimental studies show that the efficacy of the three currently licensed anti-TNF agents (infliximab, etanercept and adalimumab) may vary and depend on the type of ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness of vedolizumab (Entyvio) versus ustekinumab (Stelara) and of each ...